智通财经APP讯，迪哲医药(688192.SH)发布公告，公司自主研发的全球创新型高选择性腺苷A2aR拮抗剂DZD2269的转化科学和药效学生物标志物临床研究成果在《Journal of Experimental & Clinical Cancer Research》期刊发表。
迪哲医药(688192.SH)：DZD2269研究成果在《Journal of Experimental & Clinical Cancer Research》发表
“特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布，本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”
热点新闻